Skip to main content

Drug Interactions between brivaracetam and modafinil

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

modafinil brivaracetam

Applies to: modafinil and brivaracetam

Coadministration with inhibitors of CYP450 2C19 may increase the plasma concentrations of brivaracetam, which is partially metabolized by the isoenzyme. Blood level of brivaracetam is increased by 22% or 42%, respectively, in human subjects possessing genetic variations in CYP450 2C19 with one or both mutated alleles, while production of the hydroxy metabolite is decreased by 2-fold or 10-fold, respectively. The risk of a clinically relevant CYP450 2C19-mediated interaction is considered to be low according to the manufacturer.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2016) "Product Information. Briviact (brivaracetam)." UCB Pharma Inc

Drug and food interactions

Minor

modafinil food

Applies to: modafinil

Administration with food may delay the absorption of modafinil (the racemate) and armodafinil (the R-enantiomer) without significantly affecting their overall bioavailability. According to the product labeling, modafinil's absorption may be delayed by approximately one hour if taken with food. Similarly, the time to reach peak plasma concentration (Tmax) of armodafinil may be delayed by approximately 2 to 4 hours in the fed state.

References (2)
  1. (2001) "Product Information. Provigil (modafinil)." Cephalon, Inc
  2. (2007) "Product Information. Nuvigil (armodafinil)." Cephalon Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer